Title |
Patient-derived xenografts of triple-negative breast cancer reproduce molecular features of patient tumors and respond to mTOR inhibition
|
---|---|
Published in |
Breast Cancer Research, April 2014
|
DOI | 10.1186/bcr3640 |
Pubmed ID | |
Authors |
Haiyu Zhang, Adam L Cohen, Sujatha Krishnakumar, Irene L Wapnir, Selvaraju Veeriah, Glenn Deng, Marc A Coram, Caroline M Piskun, Teri A Longacre, Michael Herrler, Daniel O Frimannsson, Melinda L Telli, Frederick M Dirbas, AC Matin, Shanaz H Dairkee, Banafshe Larijani, Gennadi V Glinsky, Andrea H Bild, Stefanie S Jeffrey |
Abstract |
Triple-negative breast cancer (TNBC) is aggressive and lacks targeted therapies. Phosphatidylinositide 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) pathways are frequently activated in TNBC patient tumors at the genome, gene expression and protein levels, and mTOR inhibitors have been shown to inhibit growth in TNBC cell lines. We describe a panel of patient-derived xenografts representing multiple TNBC subtypes and use them to test preclinical drug efficacy of two mTOR inhibitors, sirolimus (rapamycin) and temsirolimus (CCI-779). |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
United Kingdom | 1 | <1% |
Germany | 1 | <1% |
Unknown | 117 | 98% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Researcher | 24 | 20% |
Student > Ph. D. Student | 20 | 17% |
Student > Master | 13 | 11% |
Student > Bachelor | 8 | 7% |
Student > Doctoral Student | 7 | 6% |
Other | 19 | 16% |
Unknown | 28 | 24% |
Readers by discipline | Count | As % |
---|---|---|
Agricultural and Biological Sciences | 25 | 21% |
Biochemistry, Genetics and Molecular Biology | 21 | 18% |
Medicine and Dentistry | 20 | 17% |
Pharmacology, Toxicology and Pharmaceutical Science | 7 | 6% |
Computer Science | 2 | 2% |
Other | 12 | 10% |
Unknown | 32 | 27% |